Document is current
Any future updates will be listed below
-
Authors
Hjorth, Cathrine F. https://orcid.org/0000-0003-4378-8531
Damkier, Per
Stage, Tore B.
Feddersen, Søren
Hamilton-Dutoit, Stephen
Ejlertsen, Bent
Lash, Timothy L.
Bøggild, Henrik
Sørensen, Henrik T.
Cronin-Fenton, Deirdre
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R167-A11045-17-S2)
Sundhedsvidenskabelige Fakultet, Aarhus Universitet
Dansk Kræftforsknings Fond (PLESNER–FAST–Active.FID1839672)
Lundbeckfonden (R167–2013–15861)
National Cancer institute (R01CA166825)
- License Information
-
More Information
Article History
Received: 18 August 2022
Accepted: 16 December 2022
First Online: 4 January 2023
Declarations
:
: All authors declare no support in relation to the present study. TBS receives consultancy fees from Pfizer and teaching fees from Orifarm, Eisai, Novartis, and Astellas Pharma. TLL receives consulting fees and travel support for his participation in the Amgen Methods Advisory Council. BE receives institutional grants from AstraZeneca, Eli Lilly, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis. The Department of Clinical Epidemiology, Aarhus University Hospital, receives funding for other studies from European Medicines Agency and from companies in the form of research grants to (and administered by) Aarhus University.
: The Danish Data Protection Agency (AU 2016-051-000001, #808), the Regional Ethics Committee (Record no. 1-10-72-4-18) and the Danish Breast Cancer Group (DBCG) (DBCG-2018-01-04) approved the study. The use of registry-based data for scientific studies in Denmark requires no consent from the participants.
